Shots:

• The US FDA has granted BTD to MVA-BN RSV for active immunization to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged ≥ 60yrs.
• The designation is based on preliminary clinical evidence that demonstrate substantial improvement of MVA-BN RSV over available therapy on a clinically significant endpoint
• The company is planning to initiate a P-III study in 2022 and will work closely with the US FDA towards licensure of the vaccine

 Ref: Globe Newswire | Image: CPhl Online